Last reviewed · How we verify

rFVIIa, rFVIIa + TXA — Competitive Intelligence Brief

rFVIIa, rFVIIa + TXA (rFVIIa, rFVIIa + TXA) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Hemostatic agents. Area: Rare Disease.

marketed Hemostatic agents Extrinsic coagulation pathway and fibrinolysis inhibition Rare Disease Small molecule Live · refreshed every 30 min

Target snapshot

rFVIIa, rFVIIa + TXA (rFVIIa, rFVIIa + TXA) — Oslo University Hospital.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
rFVIIa, rFVIIa + TXA TARGET rFVIIa, rFVIIa + TXA Oslo University Hospital marketed Hemostatic agents Extrinsic coagulation pathway and fibrinolysis inhibition

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Hemostatic agents class)

  1. Oslo University Hospital · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). rFVIIa, rFVIIa + TXA — Competitive Intelligence Brief. https://druglandscape.com/ci/rfviia-rfviia-txa. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: